Dermata Therapeutics Entred Agreements For The Immediate Exercise Of Certain Warrants To Purchase Up To An Aggregate Of 516,336 Shares Of The Co's Common Stock, Having Exercise Prices Of $9.7665 And $32.40 Per Share
Dermata Therapeutics Entred Agreements For The Immediate Exercise Of Certain Warrants To Purchase Up To An Aggregate Of 516,336 Shares Of The Co's Common Stock, Having Exercise Prices Of $9.7665 And $32.40 Per Share
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 516,336 shares of the Company's common stock, having exercise prices of $9.7665 and $32.40 per share, issued by Dermata in November 2023 (with respect to 462,945 warrants) and May 2023 (with respect to 53,391 warrants), at a reduced exercise price of $5.16 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File No. 333-275931) and on Form S-1 (333-273170). The closing of the offering is expected to occur on or about May 21, 2024, subject to satisfaction of customary closing conditions.
Dermata Therapeutics, Inc.（納斯達克股票代碼：DRMA）（納斯達克股票代碼：DRMAW）（“Dermata” 或 “公司”）是一家專注於治療醫學和美容皮膚病和疾病的後期生物技術公司，今天宣佈簽訂最終協議，立即行使某些未償認股權證，總共購買公司普通股516,336股，行使價爲9.9美元 Dermata於2023年11月（涉及462,945份認股權證）和2023年5月（涉及53,391份認股權證）發行的每股7665美元和32.40美元，發行價爲每股行使價下調爲5.16美元。行使認股權證時可發行的普通股根據S-3表格（文件編號333-275931）和S-1表格（333-273170）上的有效註冊聲明進行登記。此次發行預計將於2024年5月21日左右結束，但須滿足慣例成交條件。
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
H.C. Wainwright & Co. 擔任本次發行的獨家配售代理。
譯文內容由第三人軟體翻譯。